Sanofi said on Wednesday it will buy U.S. biotech Dynavax Technologies for around $2.2 billion (1.9 billion euros) in an agreed deal that will add an adult hepatitis B vaccine and a promising experimental shingles shot to its portfolio. The acquisition will help the French drugmaker diversify its…
Continue reading...